RenovoRx Inc (RNXT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
RenovoRx Inc stock (RNXT) is currently trading at $1.10. RenovoRx Inc PS ratio (Price-to-Sales) is 56.56. Analyst consensus price target for RNXT is $6.69. WallStSmart rates RNXT as Sell.
- RNXT PE ratio analysis and historical PE chart
- RNXT PS ratio (Price-to-Sales) history and trend
- RNXT intrinsic value — DCF, Graham Number, EPV models
- RNXT stock price prediction 2025 2026 2027 2028 2029 2030
- RNXT fair value vs current price
- RNXT insider transactions and insider buying
- Is RNXT undervalued or overvalued?
- RenovoRx Inc financial analysis — revenue, earnings, cash flow
- RNXT Piotroski F-Score and Altman Z-Score
- RNXT analyst price target and Smart Rating
RenovoRx Inc
📊 No data available
Try selecting a different time range
Smart Analysis
RenovoRx Inc (RNXT) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
RenovoRx Inc (RNXT) Key Strengths (0)
Supporting Valuation Data
RenovoRx Inc (RNXT) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 56.6x annual revenue
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.5x book value
Low institutional interest, mostly retail-driven
Supporting Valuation Data
RenovoRx Inc (RNXT) Detailed Analysis Report
Overall Assessment
This company scores 13/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (56.56), Price/Book (4.54) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -146.60%, Operating Margin at -1203.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -146.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RNXT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RNXT's Price-to-Sales ratio of 56.56x trades 52% above its historical average of 37.29x (86th percentile), historically expensive. The current valuation is 0% below its historical high of 56.56x set in Mar 2026, and 81% above its historical low of 31.21x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~34.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for RenovoRx Inc (RNXT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
RenovoRx Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Spending 182% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact RenovoRx Inc.
Bottom Line
RenovoRx Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About RenovoRx Inc(RNXT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. The company is headquartered in Los Altos, California.